166 related articles for article (PubMed ID: 14656269)
1. Proteomic analysis for early detection of ovarian cancer: a realistic approach?
Stevens EV; Liotta LA; Kohn EC
Int J Gynecol Cancer; 2003; 13 Suppl 2():133-9. PubMed ID: 14656269
[TBL] [Abstract][Full Text] [Related]
2. High-resolution serum proteomic features for ovarian cancer detection.
Conrads TP; Fusaro VA; Ross S; Johann D; Rajapakse V; Hitt BA; Steinberg SM; Kohn EC; Fishman DA; Whitely G; Barrett JC; Liotta LA; Petricoin EF; Veenstra TD
Endocr Relat Cancer; 2004 Jun; 11(2):163-78. PubMed ID: 15163296
[TBL] [Abstract][Full Text] [Related]
3. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
4. Proteomics analysis for finding serum markers of ovarian cancer.
Cheng Y; Liu C; Zhang N; Wang S; Zhang Z
Biomed Res Int; 2014; 2014():179040. PubMed ID: 25250314
[TBL] [Abstract][Full Text] [Related]
5. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
6. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Tchabo NE; Liel MS; Kohn EC
Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
8. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.
Tang HY; Beer LA; Chang-Wong T; Hammond R; Gimotty P; Coukos G; Speicher DW
J Proteome Res; 2012 Feb; 11(2):678-91. PubMed ID: 22032327
[TBL] [Abstract][Full Text] [Related]
9. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Jordan HA; Thomas SN
Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
[TBL] [Abstract][Full Text] [Related]
10. Clinical proteomics and biomarker discovery.
Johann DJ; McGuigan MD; Patel AR; Tomov S; Ross S; Conrads TP; Veenstra TD; Fishman DA; Whiteley GR; Petricoin EF; Liotta LA
Ann N Y Acad Sci; 2004 Jun; 1022():295-305. PubMed ID: 15251975
[TBL] [Abstract][Full Text] [Related]
11. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.
Kozak KR; Amneus MW; Pusey SM; Su F; Luong MN; Luong SA; Reddy ST; Farias-Eisner R
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12343-8. PubMed ID: 14523236
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
14. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.
Tang HY; Beer LA; Tanyi JL; Zhang R; Liu Q; Speicher DW
J Proteomics; 2013 Aug; 89():165-78. PubMed ID: 23792823
[TBL] [Abstract][Full Text] [Related]
15. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
[TBL] [Abstract][Full Text] [Related]
16. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
17. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of ovarian tumours.
Rapkiewicz AV; Espina V; Petricoin EF; Liotta LA
Eur J Cancer; 2004 Nov; 40(17):2604-12. PubMed ID: 15541961
[TBL] [Abstract][Full Text] [Related]
19. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.
Simpkins F; Czechowicz JA; Liotta L; Kohn EC
Pharmacogenomics; 2005 Sep; 6(6):647-53. PubMed ID: 16143004
[TBL] [Abstract][Full Text] [Related]
20. Proteomic approaches to tumor marker discovery.
Rai AJ; Zhang Z; Rosenzweig J; Shih IeM; Pham T; Fung ET; Sokoll LJ; Chan DW
Arch Pathol Lab Med; 2002 Dec; 126(12):1518-26. PubMed ID: 12456215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
